机构:[1]National Clinical Research Study Center for Kidney Disease,State Key Laboratory for Organ Failure Research, Renal Division, Nanfang Hospital, Southern Medical University[2]Second Clinical Medical College of Guangzhou University of Chinese Medicine ,Guangdong, China广东省中医院[3]Department of Population, Family, and Reproductive Health,Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD[4]Department of Neurology,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.广东省中医院
Objective: To examine the efficacy and effect modifiers of folic acid supplementation in the prevention of stroke in regions without folic acid fortification based on relevant, up-to-date published randomized trials. Methods: Relative risk (RR) was used to measure the effect of folic acid supplementation on risk of stroke using a fixed effects model. Findings: Overall, folic acid supplementation significantly reduced the stroke risk by 11%(22 trials, n = 82,723; RR 0.89, 95% confidence interval [CI] 0.84-0.96). The effect was greater in low folate regions (2 trials, n = 24,020; Asia, 0.78, 0.67-0.90) compared to high folate regions (7 trials, n = 14,655; America, 1.05, 0.90-1.23), and among patients without folic acid fortification (11 trials, n = 49,957; 0.85; 0.77-0.94) compared with those with folic acid fortification (7 trials, n = 14,655; 1.05, 0.90-1.23). In further stratified analyses among trials without folic acid fortification, a larger beneficial effect was found in those trials that used a low dosage of folic acid (<= 0.8 mg: 0.78, 0.69-0.88) or low baseline vitamin B-12 levels (<384 pg/mL: 0.78, 0.68-0.89). In the corresponding comparison groups, the effect sizes were attenuated and insignificant (p for interaction <0.05 for both). Although the interaction tests were not significant, there might be a higher benefit in trials with a low dosage of vitamin B-12, a low prevalence of statin use, but a high prevalence of hypertension. Conclusions: Folic acid supplementation could reduce the stroke risk in regions without folic acid fortification, particularly in trials using a relatively low dosage of folic acid and with low vitamin B12 levels.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81473052, 81402735]; National Science and Technology Major Projects Specialized for "Precision Medicine Research" during the 13th Five-Year Plan Period [2016YFC0903100]; National Key Technologies RD ProgramNational Key Technology R&D Program [2016 YFC0904900]; NSFC Innovative Group grant [81521003]; Science, Technology and Innovation Committee of Shenzhen [JCYL20130401162636527]; Department of Development and Reform, Shenzhen Municipal Government [SFG 20201744]; Special Project on the Integration of Industry, Education and Research of Guangdong Province [2011A091000031]; Science and Technology Planning Project of Guangdong Province, China [2014B090904040, 201604020003]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2016M592513]
第一作者机构:[1]National Clinical Research Study Center for Kidney Disease,State Key Laboratory for Organ Failure Research, Renal Division, Nanfang Hospital, Southern Medical University[4]Department of Neurology,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
通讯作者:
推荐引用方式(GB/T 7714):
Zhao Min,Wu Guangliang,Li Youbao,et al.Meta-analysis of folic acid efficacy trials in stroke prevention Insight into effect modifiers[J].NEUROLOGY.2017,88(19):1830-1838.doi:10.1212/WNL.0000000000003909.
APA:
Zhao, Min,Wu, Guangliang,Li, Youbao,Wang, Xiaobin,Hou, Fan Fan...&Cai, Yefeng.(2017).Meta-analysis of folic acid efficacy trials in stroke prevention Insight into effect modifiers.NEUROLOGY,88,(19)
MLA:
Zhao, Min,et al."Meta-analysis of folic acid efficacy trials in stroke prevention Insight into effect modifiers".NEUROLOGY 88..19(2017):1830-1838